US · USD
HALO
Halozyme Therapeutics Inc
- Day's range
- $107.68 – $109.87
- Day's volume
- $157M
- 52-week range
- $61.63 – $115.22
Follow HALO in the Fuolio
See how HALO weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountHALO in numbers
- Market cap
- $12.3B
- P/E
- 29.72
- P/B
- 85.64
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- 3.24
HALO trades at 29.72 times its earnings of the last 12 months.
HALO price history
HALO risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +51.69% | +180.52% | +229.41% |
| Volatility (annualized) | 35.68% | 37.06% | 40.52% |
| Largest drawdown | -11.23% | -25.12% | -43.89% |
| Positive months | 6/12 | 19/36 | 31/60 |
How much did investing in HALO return?
$1,000.00 invested on 11/01/2021 would be worth $3,294.10 today.
- Value today in HALO
- $3,294.10
- Return over the period
- +229.41%
- Return per year
- +27.38%
- In the S&P 500
- $1,702.20
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
HALO fundamentals
Valuation
- P/E29.72
- P/B85.64
- EV/EBITDA23.33
- EV/EBIT23.91
- EV/Revenue8.58
- P/EBIT20.58
- P/S7.39
- P/OCF15.02
- P/FCF15.25
- Earnings yield4.18%
- PEG ratio—
- Earnings per share$3.64
- Book value per share$1.26
Debt
- Net debt$2B
- Net debt/EBITDA3.24
- Net debt/Equity13.82
- Debt/Equity14.95
- Current ratio2.71
- Quick ratio2.31
- Cash ratio0.47
Efficiency
- Gross margin82.42%
- EBITDA margin36.78%
- Operating margin35.90%
- Net margin24.86%
- Asset turnover0.65
Profitability
- ROE288.13%
- ROA16.05%
- ROIC19.91%
- Payout0.00%
Growth
- Revenue CAGR (5 years)32.17%
- Earnings CAGR (5 years)12.58%
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is HALO's fair price?
Two classic value formulas, with today's numbers. The current price is $108.31.
- Graham's fair price
- $10.18
- 90.60% below the price
√(22.50 × $3.64 × $1.26)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to HALO: it paid no distributions in the last five years.
Décio Bazin only bought stocks yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years over 6%.
Graham ignores growth and debt; Bazin assumes past distributions repeat. They are references to compare, not a buy recommendation.
HALO's indicators by year
Multiples at each year's closing price; margins and returns from that year's statements.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | 25.06 | 13.26 | 16.65 | 38.11 | 13.75 | 44.76 | -33.93 | -26.41 |
| P/B | 162.71 | 16.18 | 55.93 | 45.36 | 28.11 | 38.25 | 26.71 | 8.53 |
| EV/EBITDA | 20.71 | 12.96 | 17.40 | 32.75 | 22.57 | 40.85 | — | — |
| Earnings per share | $2.69 | $3.61 | $2.22 | $1.49 | $2.92 | $0.95 | -$0.52 | -$0.55 |
| Book value per share | $0.41 | $2.95 | $0.66 | $1.25 | $1.43 | $1.12 | $0.66 | $1.72 |
| ROE | 649.18% | 122.06% | 336.00% | 119.04% | 204.47% | 85.46% | -78.72% | -32.28% |
| ROIC | 15.47% | 25.06% | 18.63% | 15.07% | 28.89% | 35.95% | -18.07% | -21.85% |
| Gross margin | 83.62% | 84.30% | 76.80% | 78.90% | 81.64% | 83.79% | 76.76% | 93.33% |
| EBITDA margin | 34.40% | 55.33% | 42.04% | 41.51% | 62.91% | 55.14% | -32.42% | -44.08% |
| Net margin | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | -36.86% | -52.90% |
| Net debt/EBITDA | 4.18 | 2.47 | 3.96 | 4.64 | 2.72 | 1.69 | — | — |
HALO's financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | $1.4B | $1B | $829.3M | $660.1M | $443.3M | $267.6M |
| Cost of revenue | -$228.8M | -$159.4M | -$192.4M | -$139.3M | -$81.4M | -$43.4M |
| Gross profit | $1.2B | $855.9M | $636.9M | $520.8M | $361.9M | $224.2M |
| EBITDA | $480.4M | $561.7M | $348.7M | $274M | $278.9M | $147.5M |
| EBIT | $469M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M |
| Financial result | — | — | — | — | — | — |
| Income before tax | $466.9M | $557.1M | $348.3M | $248.9M | $248.5M | $129.3M |
| Income tax | -$150M | -$113M | -$66.7M | -$46.8M | $154.2M | -$217K |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does HALO pay dividends?
HALO has no distributions on record.
About Halozyme Therapeutics
- Sector
- Manufacturing
Questions about HALO
How much is HALO today?
HALO is at $108.31 (-1.41% on the day), last traded on 10/05/2026.
What are the P/E and P/B of HALO?
HALO trades at a P/E of 29.72 and a P/B of 85.64.
How much did HALO return in 12 months?
HALO returned 51.69% in 12 months, with annualized volatility of 35.68% and a largest drawdown of -11.23%.